DK0934259T3 - Beta-sulfonamidohydroxamsyrer som matrixmetalloproteinase- og TACE-inhibitorer - Google Patents

Beta-sulfonamidohydroxamsyrer som matrixmetalloproteinase- og TACE-inhibitorer

Info

Publication number
DK0934259T3
DK0934259T3 DK97912674T DK97912674T DK0934259T3 DK 0934259 T3 DK0934259 T3 DK 0934259T3 DK 97912674 T DK97912674 T DK 97912674T DK 97912674 T DK97912674 T DK 97912674T DK 0934259 T3 DK0934259 T3 DK 0934259T3
Authority
DK
Denmark
Prior art keywords
sulfonamidohydroxamic
beta
acids
matrix metalloproteinase
tace inhibitors
Prior art date
Application number
DK97912674T
Other languages
English (en)
Inventor
Jeremy Ian Levin
Yansong Gu
Arie Zask
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Application granted granted Critical
Publication of DK0934259T3 publication Critical patent/DK0934259T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
DK97912674T 1996-10-16 1997-10-08 Beta-sulfonamidohydroxamsyrer som matrixmetalloproteinase- og TACE-inhibitorer DK0934259T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72935996A 1996-10-16 1996-10-16
PCT/US1997/018170 WO1998016506A1 (en) 1996-10-16 1997-10-08 Beta-sulfonamido hydroxamic acids as matrix metalloproteinase and tace inhibitors

Publications (1)

Publication Number Publication Date
DK0934259T3 true DK0934259T3 (da) 2003-01-27

Family

ID=24930685

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97912674T DK0934259T3 (da) 1996-10-16 1997-10-08 Beta-sulfonamidohydroxamsyrer som matrixmetalloproteinase- og TACE-inhibitorer

Country Status (18)

Country Link
EP (1) EP0934259B1 (da)
JP (1) JP2001502326A (da)
KR (1) KR20000049198A (da)
CN (1) CN1105101C (da)
AR (1) AR008676A1 (da)
AT (1) ATE224364T1 (da)
AU (1) AU736134B2 (da)
BR (1) BR9712524A (da)
CA (1) CA2268895A1 (da)
DE (1) DE69715647T2 (da)
DK (1) DK0934259T3 (da)
ES (1) ES2184069T3 (da)
HK (1) HK1020720A1 (da)
IL (1) IL129149A (da)
NZ (1) NZ335053A (da)
PT (1) PT934259E (da)
WO (1) WO1998016506A1 (da)
ZA (1) ZA979236B (da)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69917124T2 (de) * 1998-04-10 2005-05-12 Pfizer Products Inc., Groton Cyclobutyl-Aryloxysulfonylamin-Hydroxamsäurederivate
WO1999065867A1 (en) * 1998-06-17 1999-12-23 Du Pont Pharmaceuticals Company Cyclic hydroxamic acids as metalloproteinase inhibitors
US6326516B1 (en) 1999-01-27 2001-12-04 American Cyanamid Company Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors
US6313123B1 (en) 1999-01-27 2001-11-06 American Cyanamid Company Acetylenic sulfonamide thiol tace inhibitors
US6946473B2 (en) 1999-01-27 2005-09-20 Wyeth Holdings Corporation Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors
US6225311B1 (en) 1999-01-27 2001-05-01 American Cyanamid Company Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors
US6762178B2 (en) 1999-01-27 2004-07-13 Wyeth Holdings Corporation Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
US6200996B1 (en) 1999-01-27 2001-03-13 American Cyanamid Company Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
US6753337B2 (en) 1999-01-27 2004-06-22 Wyeth Holdings Corporation Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
US6340691B1 (en) 1999-01-27 2002-01-22 American Cyanamid Company Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors
CN1178915C (zh) 1999-01-27 2004-12-08 惠氏控股有限公司 含有炔基的异羟肟酸衍生物、其制备及其作为基质金属蛋白酶抑制剂/TNF-α转变酶抑制剂的用途
US6277885B1 (en) 1999-01-27 2001-08-21 American Cyanamid Company Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
AU2320500A (en) * 1999-02-02 2000-08-25 Shionogi & Co., Ltd. Sulfonamide derivatives having cyclic structures
IL153045A0 (en) * 2000-05-23 2003-06-24 Osmonics Inc Modified sulfonamide polymers
MXPA04004010A (es) 2001-11-01 2004-07-23 Wyeth Corp Acidos hidroxamicos de aril sulfonamida alenicos como inhibidores de tace y metaloproteinasa de matriz.
US7491718B2 (en) 2002-10-08 2009-02-17 Abbott Laboratories Sulfonamides having antiangiogenic and anticancer activity
US20040157836A1 (en) * 2002-10-08 2004-08-12 Comess Kenneth M. Sulfonamides having antiangiogenic and anticancer activity
WO2005021489A2 (en) 2002-12-23 2005-03-10 Wyeth Holdings Corporation Acetylenic aryl sulfonate hydroxamic acid tace and matrix metalloproteinase inhibitors
WO2005092844A1 (en) * 2004-03-22 2005-10-06 Southern Research Institute Nonpeptide inhibitors of matrix metalloproteinases
FR2947270B1 (fr) * 2009-06-30 2011-08-26 Galderma Res & Dev Nouveaux composes benzene-sulfonamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique
FR2947268B1 (fr) 2009-06-30 2011-08-26 Galderma Res & Dev Nouveaux composes benzene-sulfonamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique
US20140275108A1 (en) 2013-03-15 2014-09-18 Galderma Research & Development Novel benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine as well as in cosmetics
IL237852A0 (en) 2015-03-19 2016-03-24 Yeda Res & Dev Antibodies against amphigoline, medical preparations containing them and their use
WO2017117130A1 (en) 2015-12-28 2017-07-06 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for inhibiting human immunodeficiency virus (hiv) release from infected cells
EP3199534B1 (en) 2016-02-01 2018-09-05 Galderma Research & Development Benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine and cosmetics
US20210393632A1 (en) 2018-10-04 2021-12-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Egfr inhibitors for treating keratodermas

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
EP0692931A4 (en) * 1993-04-07 1996-03-20 Glycomed Inc SYNTHETIC INHIBITORS OF MATRIX METALLOPROTEASE AND USES
US5672598A (en) * 1995-03-21 1997-09-30 The Procter & Gamble Company Lactam-containing hydroxamic acids

Also Published As

Publication number Publication date
CN1105101C (zh) 2003-04-09
NZ335053A (en) 2000-10-27
IL129149A (en) 2003-10-31
ZA979236B (en) 1999-07-15
CN1240424A (zh) 2000-01-05
EP0934259A1 (en) 1999-08-11
PT934259E (pt) 2003-01-31
ATE224364T1 (de) 2002-10-15
CA2268895A1 (en) 1998-04-23
JP2001502326A (ja) 2001-02-20
IL129149A0 (en) 2000-02-17
DE69715647D1 (en) 2002-10-24
DE69715647T2 (de) 2003-02-20
WO1998016506A1 (en) 1998-04-23
HK1020720A1 (en) 2000-05-19
KR20000049198A (ko) 2000-07-25
EP0934259B1 (en) 2002-09-18
BR9712524A (pt) 1999-10-19
AU4979097A (en) 1998-05-11
AR008676A1 (es) 2000-02-09
ES2184069T3 (es) 2003-04-01
AU736134B2 (en) 2001-07-26

Similar Documents

Publication Publication Date Title
DK0934259T3 (da) Beta-sulfonamidohydroxamsyrer som matrixmetalloproteinase- og TACE-inhibitorer
DK0938471T3 (da) Fremstillingen og anvendelsen af ortho-sulfonamido-arylhydroxamsyrer som matrix-metalloproteinase- og TACE-inhibitorer
NO991922L (no) Heteroarylsuccinamider og deres anvendelse som metalloproteinaseinhibitorer
NO972307D0 (no) Matriksmetallproteaseinhibitorer
DK0873312T3 (da) Alfa-substituerede arylsulfonamidohydroxamsyrer som TNF-alfa- og matrix-metalloproteinaseinhibitorer
ATE257151T1 (de) Hydroxamsäure-derivate als matrix metalloproteinaseinhibitoren
DK0925303T3 (da) Phosphinsyreamider som matrixmetalloproteaseinhibitorer
NO995433D0 (no) Protease-inhibitorer
DK0944590T3 (da) Aminoguanidiner og alkoxyguanidiner som proteaseinhibitorer
NO974403D0 (no) Reversible proteasehemmere
NO995434L (no) Proteaseinhibitorer
NO994103D0 (no) Reverse hydroksamatderivater som metallproteaseinhibitorer
NO995435D0 (no) Protease-inhibitorer
NO995268D0 (no) Proteaseinhibitorer
BR9709902A (pt) Inibidores de metalo-proteinase de matriz
NO20002938L (no) Fibrinolytisk inhibitor som forseglingsmateriale
DK0937036T3 (da) Substituerede 4-biphenyl-4-hydroxysmørsyrederivater som matrixmetalprotease-inhibitorer
DK1047665T3 (da) Matrix metalloprotease inhibitorer
NO20003828D0 (no) 2,3,4,5-Tetrahydro-1H-[1,4]-benzodiazepin-3-hydroksamsyrer som matriks-metalloproteinaseinhibitorer
TR199501429A2 (tr) Matriks metaloproteaz inhibitörlerinin yerine gecen 4-biarilpentanoik asitleri ve türevleri
NO965353D0 (no) 3-amino-2-okso-1-piperidineddiksyrederivater som enzyminhibitorer
ATE228999T1 (de) Metalloproteinaseinhibitoren
ID17775A (id) Asam-asam bifenil butirat dan turunan-turunannya sebagai inhibitor matriks metaloproteinase